The Post–CAR T Journey: Long-Term Monitoring, Multidisciplinary Care, and Continuous Patient Support
Panelists discuss how health care centers provide comprehensive long-term monitoring and support services for both patients receiving CAR T and their caregivers in the posttreatment period, including regular medical assessments and ongoing educational resources.
EP: 1.A High-Risk Myeloma Patient’s Path to CAR T: Personal and Clinical Perspectives
EP: 2.Behind the Scenes: Patient Education and Decision-Making for CAR T
EP: 3.Clinical Data Supporting CAR T in Earlier Lines: Updates From the CARTITUDE-1, CARTITUDE-4, and KarMMa-3 Trials
EP: 4.The Real-World Logistics of CAR T Therapy: Financial and Practical Considerations
EP: 5.From Collection to Infusion: Comprehensive CAR T Treatment and Management Strategies From CAR T Specialists
EP: 6.The Post–CAR T Journey: Long-Term Monitoring, Multidisciplinary Care, and Continuous Patient Support
EP: 7.Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
Video content above is prompted by the following:
- What specific long-term monitoring protocols and support services does your center provide for patients undergoing CAR T and their caregivers in the months and years following treatment (eg, monitoring and care, support services, caregiver education, etc)?
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
